Logo
x

Search

Subscribe Now

inxmed

InxMed’s Ifebemtinib Secures the NMPA’s Breakthrough Therapy Designation as a 1L Treatment of KRAS G12C Mutated NSCLC

InxMed’s Ifebemtinib Secures the NMPA’s Breakthrough Therapy Designation as a 1L Treatment of KRAS G12C Mutated NSCLC

  • November 21, 2024
InxMed Reveals Data from the P-Ib/II Study of Ifebemtinib Plus Garsorasib for Non-Small Cell Lung Cancer (NSCLC)

InxMed Reveals Data from the P-Ib/II Study of Ifebemtinib Plus Garsorasib for Non-Small Cell Lung Cancer (NSCLC)

  • May 30, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.